Oppenheimer Raises Price Target on Tarsus Pharmaceuticals to $103

On November 4, 2026, investment firm Oppenheimer adjusted its outlook on Tarsus Pharmaceuticals, raising the price target on the company's stock from $100 to $103. The firm maintained its Outperform rating on the shares. This analyst action follows the company's recent third-quarter 2026 financial reporting.